Track Wockhardt Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: 20.18 %
Low
1,837.0
High
2,240.0
1 Month returns: 10.04 %
Low
1,814.4
High
2,240.0
1 Year returns: 52.32 %
Low
1,086.7
High
2,422.3
3 Year CAGR: 104.52 %
Low
213.3
High
2,422.3
5 Year CAGR: 42.15 %
Low
145.1
High
2,422.3
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Wockhardt Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Wockhardt Ltd. Shareholding Pattern
Quarterly breakdown of Wockhardt Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Wockhardt Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Wockhardt Ltd.?
The current share price of Wockhardt Ltd. is ₹ 2,224.00 as of 8 Sep 2026.
What is the market capitalisation of Wockhardt Ltd.?
The market capitalisation of Wockhardt Ltd. stands at ₹ 36,138.20 Cr.
What is the PE ratio of Wockhardt Ltd.?
The Price-to-Earnings (PE) ratio of Wockhardt Ltd. is 88.36 as of the latest trailing twelve months data.
What is the ROE and ROCE of Wockhardt Ltd.?
Wockhardt Ltd. has a Return on Equity (ROE) of 4.58% and a Return on Capital Employed (ROCE) of 5.68% as per the latest financial reports.
What is the 52-week high and low of Wockhardt Ltd.?
The 52-week high of Wockhardt Ltd. is - and the 52-week low is -.
What is the dividend yield of Wockhardt Ltd.?
The dividend yield of Wockhardt Ltd. is 0.00% based on the current market price.
What is the FII and DII holding in Wockhardt Ltd.?
Foreign Institutional Investors (FII) hold 7.23%, Domestic Institutional Investors (DII) hold 7.00% and retail/public investors hold 31.64% of Wockhardt Ltd. shares.
What sector does Wockhardt Ltd. belong to?
Wockhardt Ltd. operates in the Healthcare sector.
What is the beta of Wockhardt Ltd.?
The beta of Wockhardt Ltd. is 0.89, indicating its price volatility relative to the broader market. Over the past 1 year, Wockhardt Ltd. has delivered an absolute return of 57.17%.
What is the RSI of Wockhardt Ltd.?
The 14-day Relative Strength Index (RSI) of Wockhardt Ltd. is 70.88, placing it in the overbought zone. An RSI above 70 is considered overbought and below 30 is considered oversold.
Mar 2020
Jun 2020
Sep 2020
Dec 2020
Mar 2021
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Promoter
72.13
72.13
72.12
72.12
72.12
69.68
68.04
67.13
67.13
65.75
63.83
60.36
59.31
58.40
55.14
54.93
51.60
51.99
51.99
49.09
49.09
49.09
49.08
49.08
49.08
49.08
Indian Promoter
72.13
72.13
72.12
72.12
72.12
69.68
68.04
67.13
67.13
65.75
63.83
60.36
59.31
58.40
55.14
54.93
51.60
51.99
51.99
49.09
49.09
49.09
49.08
49.08
49.08
49.08
Foreign Promoter
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Institutions
5.09
4.90
4.69
4.12
3.19
2.82
2.93
3.04
2.98
2.91
3.13
3.09
3.00
2.77
3.23
4.48
10.33
10.39
11.81
16.38
17.42
18.31
18.12
17.55
18.08
16.47
Mutual Funds / UTI
0.00
0.00
0.01
0.01
0.01
0.02
0.02
0.03
0.03
0.03
0.03
0.04
-
-
0.03
0.09
3.11
2.91
2.95
7.13
7.56
8.02
7.89
7.76
8.12
6.79
FI/Bank/Insurance
0.14
0.15
0.01
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.47
0.51
0.46
0.66
0.31
0.06
0.21
Govt
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
0.01
0.01
0.02
0.02
0.02
0.02
0.02
0.02
0.04
0.02
FII
4.85
4.69
4.63
4.07
3.10
2.74
2.87
2.95
2.89
2.82
2.98
2.87
2.78
2.60
3.03
4.18
5.49
5.94
6.70
6.54
6.83
7.29
7.10
7.00
7.09
7.23
Other Institutions
0.09
0.06
0.05
0.05
0.08
0.06
0.04
0.06
0.07
0.08
0.12
0.18
0.22
0.18
0.18
0.21
1.71
1.54
2.13
2.21
2.51
2.52
2.44
2.47
2.77
2.23
Non-Institution
22.78
22.97
23.19
23.75
24.69
27.49
29.02
29.83
29.89
31.34
33.03
36.55
37.69
38.82
41.62
40.59
38.07
37.61
36.21
34.53
33.49
32.60
32.80
33.36
32.84
34.45
Bodies Corporate
1.96
1.69
1.02
1.12
0.82
1.20
1.12
1.15
2.35
2.00
3.01
3.29
3.31
3.53
5.30
4.28
4.63
3.95
3.46
3.52
3.29
3.15
2.48
2.62
2.61
2.81
Others (incl. Retail)
No. of shareholders
20.82
1,16,538
21.28
1,18,901
22.17
1,29,606
22.63
1,13,324
23.87
1,24,848
26.29
1,44,076
27.90
1,60,879
28.68
1,64,513
27.54
1,71,709
29.34
1,79,381
30.02
1,79,779
33.26
1,84,041
34.38
1,81,645
35.29
1,78,043
36.32
1,72,118
36.31
1,60,911
33.44
1,45,147
33.66
1,39,336
32.75
1,36,801
31.01
1,41,478
30.20
1,40,552
29.45
1,45,625
30.32
1,36,779
30.74
1,41,100
30.23
1,37,876
31.64
1,65,163
Stock Analysis
Fundamental analysis overview of Wockhardt Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Strong price momentum
Price Momentum score of 90.7 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term
What is Price Momentum score?
90.7 / 100
Moderate operating margin but improving trend
The company reported moderate operating margin of 13.78% for 12-month ended 30 Jun 2026 but operating margin improved by 757 bps from 1 year ago
What is Operating profit margin?
Moderate revenue growth and above median growth of industry
The company delivered moderate revenue growth of 18.37% for 12-month ended 30 Jun 2026 and the growth was 7.78 percentage points higher than median growth of industry
What is Sales growth (1Y)?
Median: 10.59
Value 18.37
-99.6111701.8
Low Debt to Equity, not much change from last year
The company has low Debt to Equity of 0.45 as on 30 Jun 2026 and Debt to Equity decreased marginally by 0.01 in the last 1 year
What is Debt to Equity?
Negative
Expensive and at a premium to industry median P/E
PE TTM of 88.36 indicates that the stock is expensive on a standalone basis and is at a 178.04% premium to industry median P/E
What is P/E Ratio?
Median: 31.78
Value 88.36
-0.96721.13
Low dividend yield
The company has a low dividend yield of 0.0%
What is Dividend yield?
Neutral
Low ROE but improving trend
The company reported low ROE of 4.58% for 12-month ended 30 Jun 2026 but ROE improved by 580 bps from 1 year ago
What is ROE (FY)?
Company's earnings are of moderate quality
Earnings quality score of 58.3 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
58.3 / 100
No red flags found!
No significant red flags found in the stock.
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Holdings and Presence
Indices and prominent investors with a stake in this stock.
History of Wockhardt Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.
Rights Issue(3 new shares @ ₹225 for 10 existing shares)
Ex-date: 8th Mar 2022Announced on: 3rd Mar 2022
Dividend₹ 10/share
Record date: 19th Nov 2016Ex-date: 17th Nov 2016
Announced on: 28th Oct 2016
Dividend₹ 20/share
Record date: 15th Nov 2014Ex-date: 13th Nov 2014
Announced on: 3rd Nov 2014
Dividend₹ 5/share
Record date: 19th Feb 2014Ex-date: 17th Feb 2014
Announced on: 10th Feb 2014
Dividend₹ 5/share
Record date: 8th Nov 2013Ex-date: 7th Nov 2013
Announced on: 25th Oct 2013
2,224.0016.0 (0.72%)
52.32% in past 1 year
Name
Month
Transaction
Holding % pre transaction
Average price
Qty.
Transaction value
Themisto Trustee Company Private Limited
Promoter Group
September-2021
Market Sale (Disposal)
1st Sep 2021
54.15 %
₹ 432.64
5.00 lac
₹ 21.63 cr
Ananke Trustee Company Private Limited
Promoter Group
September-2021
Market Sale (Disposal)
1st Sep 2021
0.88 %
₹ 399.11
3.00 lac
₹ 11.97 cr
Pasithee Trustee Company Private Limited
Promoter Group
September-2021
Market Sale (Disposal)
1st Sep 2021
0.90 %
₹ 410.42
3.00 lac
₹ 12.31 cr
Pasithee Trustee Company Private Limited
Promoter Group
September-2021
Market Sale (Disposal)
1st Sep 2021
0.63 %
₹ 399.13
2.00 lac
₹ 7.98 cr
Themisto Trustee Company Private Limited
Promoter Group
September-2021
Market Sale (Disposal)
1st Sep 2021
3.43 %
₹ 441.42
5.00 lac
₹ 22.07 cr
Akhilesh Gupta
Director
August-2021
Market Purchase (Acquisition)
31st Aug 2021
0.00 %
₹ 439.33
10.00 k
₹ 43.93 lac
Callirhoe Trustee Company Private Limited
Promoter Group
July-2021
Market Sale (Disposal)
2nd Jul 2021
0.74 %
₹ 519.00
1.00 lac
₹ 5.19 cr
Themisto Trustee Company Private Limited
Promoter Group
July-2021
Market Sale (Disposal)
2nd Jul 2021
3.88 %
₹ 526.60
5.00 lac
₹ 26.33 cr
Themisto Trustee Company Private Limited
Promoter Group
June-2021
Market Sale (Disposal)
28th Jun 2021
3.97 %
₹ 539.00
1.00 lac
₹ 5.39 cr
Ananke Trustee Company Private Limited
Promoter Group
June-2021
Market Sale (Disposal)
28th Jun 2021
1.33 %
₹ 558.60
5.00 lac
₹ 27.93 cr
Company Profile
Overview of Wockhardt Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generi...